Table 4 Association between genome-wide significant SNPs and clinical characteristics of gout.

From: Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease

Affected joints

Controls

Cases

% of female cases

SLC2A9 rs12498742 (G)

ABCG2 rs2231142 (T)

OR (95%CI)

p-value

OR (95%CI)

p-value

shoulder

2007

19

26.3%

0.67 (0.25–1.47)

3.6E-01

0.38 (0.06–1.27)

1.9E-01

elbow

1988

38

10.5%

0.36 (0.15–0.73)

9.7E-03

0.92 (0.42–1.77)

8.2E-01

wrist

1959

67

23.9%

0.35 (0.18–0.60)

4.7E-04

1.18 (0.70–1.89)

5.1E-01

finger

1929

97

35.1%

0.73 (0.49–1.04)

9.7E-02

0.64 (0.37–1.04)

9.3E-02

knee

1928

98

7.1%

0.59 (0.39–0.87)

1.0E-02

1.41 (0.94–2.07)

8.7E-02

ankle

1903

123

14.6%

0.67 (0.47–0.93)

2.3E-02

1.47 (1.02–2.08)

3.2E-02

toe

1504

522

20.5%

0.92 (0.77–1.09)

3.3E-01

1.15 (0.93–1.43)

1.9E-01

midfoot

1816

210

21.4%

0.61 (0.46–0.80)

4.2E-04

1.31 (0.97–1.73)

7.0E-02

  1. Covariates included age, sex and log (eGFR). OR: Odds Ratio, 95% CI: 95% Confidence interval. For SLC2A9, rs12498742 is the previously reported index SNP from the GUGC Consortium; it is in LD with rs13111638 (r2 = 0.74, D′ = 0.98), the index SNP for SLC2A9 in the GCKD study. The p-value adjusted for multiple testing was p < 3.1E-03 (in bold).
Back to article page